Have a look at how we are constantly developing ways to fight this battle.
How we’ve made a difference
We found that a genetic variant that is found in 60% of Asians (and only 15% of Caucasians and <5% of Africans) is associated with breast cancers that have activated immune systems and recently completed a clinical trial testing whether Asian patients with this genetic variant may be treated with methods that harnesses the patient’s own immune system to target cancer cells.
We have also developed a new method to identify breast cancer patients whose tumours are BRCA-like, even though the patients do not have the BRCA gene variant and are conducting a clinical trial testing whether Asian patients with aggressive breast cancer may be treated with newer therapies targeting the BRCA-like features.
Developed a cancer vaccine that is able to control tumour growth by up to 97% and licensed this to a biopharmaceutical company for human clinical trials.
Developed a collaboration with Ministry of Health and 9 hospitals in Malaysia to test the effectiveness of lower (and more affordable) doses of immunotherapy for treatment of lung cancers.
What we’re doing now
We are working on turning the above discoveries into new or repurposed treatments for patients.